V. Parks

发表

Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating Women

Kyle T. Matschke, J. Korth-Bradley, P. Bryson, 2011, Antimicrobial Agents and Chemotherapy.

Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS‐233 SR) in healthy subjects

A. Patat, V. Parker, J. Behrle, 2005 .

Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2012, Clinical pharmacology in drug development.

The Effect of a High-Fat Breakfast on the Pharmacokinetics of Moxidectin in Healthy Male Subjects: A Randomized Phase I Trial

Kyle T. Matschke, J. Korth-Bradley, S. Chalon, 2012, The American journal of tropical medicine and hygiene.

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2013, European Journal of Clinical Pharmacology.

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2013, European Journal of Clinical Pharmacology.

Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Severe Hepatic Impairment

A. Patat, R. Moirand, Kyle T. Matschke, 2008, Journal of clinical pharmacology.

Bioequivalence & Bioavailability

J. Posener, A. Patat, J. Paul, 2011 .

Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects.

A. Patat, G. Ferron, S. Troy, 2003, British journal of clinical pharmacology.

Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects

Kyle T. Matschke, S. Chalon, S. Ripp, 2014, Clinical pharmacology in drug development.

Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.

A. Patat, D. Chassard, A. Płotka, 2009, British journal of clinical pharmacology.

Effect of anagrelide on cardiac repolarization in healthy volunteers: a randomized, double‐blind, placebo‐ and positive‐controlled, thorough QT study

S. Troy, Patrick Martin, M. Armstrong, 2014 .

Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin

A. Patat, Honghui Zhou, J. Korth-Bradley, 2004, Journal of clinical pharmacology.

A Positron Emission Tomography Study to Assess Binding of Lecozotan, a Novel 5‐Hydroxytryptamine‐1A Silent Antagonist, to Brain 5‐HT1A Receptors in Healthy Young and Elderly Subjects, and in Patients With Alzheimer's Disease

B. Långstrom, A. Patat, J. Paul, 2008, Clinical pharmacology and therapeutics.

Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin

A. Patat, D. Simcoe, Honghui Zhou, 2004, Journal of clinical pharmacology.

Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study

A. Płotka, S. Chalon, L. Schechter, 2008, European Neuropsychopharmacology.

Lack of Pharmacokinetic Interaction Co‐Administered of Sirolimus and Tacrolimus

A. Patat, J. Zimmerman, V. Parks, 2003 .

Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study

A. Płotka, S. Chalon, L. Schechter, 2008, European Neuropsychopharmacology.